GRTX Galera Therapeutics, Inc.

Galera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis. It is also involved in developing GC4711, which is in Phase I clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is based in Malvern, Pennsylvania.

As of 10/18/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/07/2019
Outstanding shares:  26,365,632
Average volume:  75,120
Market cap:   $205,915,586
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    36338D108
ISIN:        US36338D1081
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   -7.65
PS ratio:   0.00
Return on equity:   306.64%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy